Daiichi Kigenso Kagaku Kogyo (4082) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
13 Jul, 2026Executive summary
Net sales for 1Q–3Q FY3/2026 reached ¥26,314mn, up 5.0% year-over-year, with operating profit at ¥2,736mn, up 17.5% year-over-year, driven by solid performance in automotive catalyst and basic areas, and cost reductions in the Vietnam subsidiary.
Ordinary profit increased 15.5% year-over-year to ¥2,328mn.
Profit attributable to owners of parent was ¥1,992mn, up 24% year-over-year.
Full-scale operations at the Vietnam factory since July 2025 contributed to stable production and cost efficiency, supporting supply chain resilience and added value for customers.
Upward revisions to the full-year earnings forecast were announced in February 2026, reflecting stronger-than-expected demand and cost control.
Financial highlights
Gross profit for 1Q–3Q FY3/2026 was ¥7,679mn, up 13.2% year-over-year; operating profit margin improved to 10.4% from 9.3%.
Comprehensive income for the period was ¥150mn, down 78.4% year-over-year.
Basic earnings per share for the nine months was ¥65.92; diluted EPS was ¥58.25.
Total assets as of December 31, 2025, were ¥65,570mn; net assets were ¥37,893mn.
Depreciation costs for the period were ¥2,458mn; R&D costs totaled ¥997mn.
Outlook and guidance
FY3/2026 net sales forecast revised upward to ¥35,300mn (+4.9% YoY), with operating profit expected at ¥3,200mn (+40.2% YoY) and profit attributable to owners of parent at ¥1,700mn (+114.6% YoY).
Ordinary profit forecast is ¥2,400mn, up 279.6% year-over-year.
Basic earnings per share forecast is ¥70.16 for the full year.
Cost reductions in Vietnam and SG&A are progressing faster than planned, supporting higher profit expectations.
Automotive catalyst demand remains steady, offsetting weakness in some automotive-related products.
Latest events from Daiichi Kigenso Kagaku Kogyo
- Operating profit rose 8.2% despite lower sales and a net loss from special charges.4082
Q2 202513 Jul 2026 - Operating profit surged 73.2% on strong healthcare and semiconductor sales, despite net income decline.4082
Q1 202513 Jul 2026 - Net income rose 19% YoY despite a 6.2% revenue decline, driven by special gains.4082
Q3 202513 Jul 2026 - Sales and profits fell year-over-year, with further profit decline forecast for FY2026.4082
Q4 202513 Jul 2026 - Profits fell sharply due to exchange losses, but the dividend is set to rise.4082
Q1 202613 Jul 2026 - Net sales grew slightly YoY, but profit fell; guidance and dividends were raised on Vietnam cost cuts.4082
Q2 202613 Jul 2026 - Operating profit surged 52.4% YoY, but next year's outlook signals a decline in earnings.4082
Q4 202613 Jul 2026